Bolt Biotherapeutics Analyst Ratings
Bolt Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 06/05/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 05/26/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 05/12/2023 | 203.03% | SVB Leerink | → $4 | Upgrades | Market Perform → Outperform |
| 05/12/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 03/30/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 01/24/2023 | 127.27% | Morgan Stanley | $5 → $3 | Maintains | Equal-Weight |
| 10/04/2022 | 506.06% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
| 08/11/2022 | 203.03% | SVB Leerink | $8 → $4 | Downgrades | Outperform → Market Perform |
| 05/17/2022 | 278.79% | Morgan Stanley | $7 → $5 | Maintains | Equal-Weight |
| 01/06/2022 | 733.33% | Morgan Stanley | $45 → $11 | Downgrades | Overweight → Equal-Weight |
| 11/10/2021 | 2400% | SVB Leerink | $35 → $33 | Maintains | Outperform |
| 08/16/2021 | 2551.52% | SVB Leerink | $34 → $35 | Maintains | Outperform |
| 05/17/2021 | 2400% | SVB Leerink | $37 → $33 | Maintains | Outperform |
| 04/06/2021 | 2703.03% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 03/02/2021 | 2930.3% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 03/02/2021 | 3081.82% | Guggenheim | → $42 | Initiates Coverage On | → Buy |
| 03/02/2021 | 3309.09% | Morgan Stanley | → $45 | Initiates Coverage On | → Overweight |
| 03/02/2021 | 2627.27% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/03/2023 | 506.06% | HC Wainwright公司 | →$8 | 重申 | →购买 |
| 06/05/2023 | 506.06% | HC Wainwright公司 | →$8 | 重申 | 购买→购买 |
| 2023年05月26日 | 506.06% | HC Wainwright公司 | →$8 | 重申 | →购买 |
| 2023年05月12日 | 203.03% | SVB Leerink | →$4 | 升级 | 市场表现优于→ |
| 2023年05月12日 | 506.06% | HC Wainwright公司 | →$8 | 重申 | 购买→购买 |
| 03/30/2023 | 506.06% | HC Wainwright公司 | →$8 | 重申 | →购买 |
| 01/24/2023 | 127.27% | 摩根士丹利 | $5→$3 | 维护 | 等重 |
| 10/04/2022 | 506.06% | HC Wainwright公司 | →$8 | 开始承保 | →购买 |
| 2022年08月11日 | 203.03% | SVB Leerink | $8→$4 | 评级下调 | 跑赢→市场表现 |
| 2022/05/17 | 278.79% | 摩根士丹利 | $7→$5 | 维护 | 等重 |
| 01/06/2022 | 733.33% | 摩根士丹利 | $45→$11 | 评级下调 | 超重→等重 |
| 2021年11月10日 | 2400% | SVB Leerink | $35→$33 | 维护 | 跑赢大盘 |
| 08/16/2021 | 2551.52% | SVB Leerink | $34→$35 | 维护 | 跑赢大盘 |
| 2021/05/17 | 2400% | SVB Leerink | $37→$33 | 维护 | 跑赢大盘 |
| 04/06/2021 | 2703.03% | SVB Leerink | $36→$37 | 维护 | 跑赢大盘 |
| 03/02/2021 | 2930.3% | Stifel | →$40 | 开始承保 | →购买 |
| 03/02/2021 | 3081.82% | 古根海姆 | →$42 | 开始承保 | →购买 |
| 03/02/2021 | 3309.09% | 摩根士丹利 | →$45 | 开始承保 | →超重 |
| 03/02/2021 | 2627.27% | SVB Leerink | →$36 | 开始承保 | →跑赢大盘 |
What is the target price for Bolt Biotherapeutics (BOLT)?
博尔特生物疗法(Bolt)的目标价是多少？
The latest price target for Bolt Biotherapeutics (NASDAQ: BOLT) was reported by HC Wainwright & Co. on August 3, 2023. The analyst firm set a price target for $8.00 expecting BOLT to rise to within 12 months (a possible 506.06% upside). 9 analyst firms have reported ratings in the last year.
博尔特生物治疗公司(纳斯达克代码：BOLT)的最新目标价是由HC Wainwright&Co.于2023年8月3日报道的。这家分析公司将目标价定为8美元，预计博尔特将在12个月内上涨(可能上涨506.06%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Bolt Biotherapeutics (BOLT)?
博尔特生物治疗公司(Bolt)的最新分析师评级是多少？
The latest analyst rating for Bolt Biotherapeutics (NASDAQ: BOLT) was provided by HC Wainwright & Co., and Bolt Biotherapeutics reiterated their buy rating.
博尔特生物治疗公司(纳斯达克代码：BOLT)的最新分析师评级由HC Wainwright&Co.提供，博尔特生物治疗公司重申其买入评级。
When is the next analyst rating going to be posted or updated for Bolt Biotherapeutics (BOLT)?
博尔特生物疗法(Bolt)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bolt Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bolt Biotherapeutics was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Bolt BioTreateutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Bolt BioTreateutics的上一次评级是在2023年8月3日提交的，所以你应该预计下一次评级将在2024年8月3日左右的某个时候提供。
Is the Analyst Rating Bolt Biotherapeutics (BOLT) correct?
分析师对Bolt BioTreateutics(Bolt)的评级正确吗？
While ratings are subjective and will change, the latest Bolt Biotherapeutics (BOLT) rating was a reiterated with a price target of $0.00 to $8.00. The current price Bolt Biotherapeutics (BOLT) is trading at is $1.32, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Bolt BioTreateutics(Bolt)评级被重申，目标价在0.00美元至8.00美元之间。博尔特生物疗法(Bolt)目前的交易价格为1.32美元，在分析师的预测范围内。